Age, pain intensity, and opioid dose in patients with advanced cancer

被引:0
|
作者
Viganó, A
Bruera, E
Suarez-Almazor, ME [1 ]
机构
[1] Univ Alberta, Healthcare Qual & Outcomes Res Ctr, Heritage Med Res Ctr 214, Dept Med, Edmonton, AB T6G 2S2, Canada
[2] Univ Alberta, Dept Publ Hlth Sci, Edmonton, AB, Canada
[3] Univ Alberta, Div Palliat Care Med, Edmonton, AB, Canada
[4] Univ Alberta, Grey Nuns Hosp, Div Palliat Care Med, Edmonton, AB, Canada
关键词
age; cancer pain; incidental pain; neuropathic pain; opioid consumption;
D O I
10.1002/(SICI)1097-0142(19980915)83:6<1244::AID-CNCR26>3.3.CO;2-P
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Elderly patients are more likely to be affected by the acute and chronic toxicities of opioids, but an association between age and long term opioid consumption has not been established clearly in patients with advanced cancer. METHODS. The computerized records of 197 cancer patients admitted to a palliative care unit in Edmonton, Alberta, Canada were examined. The authors examined: demographics (age, gender, and location of primary tumor), pain characteristics (presence of neuropathic pain and incidental pain), mean daily pain intensity (MDPI), and daily opioid consumption measured as (parenteral) morphine equivalent daily dose (MEDD). MDPI and MEED were assessed on Days 2 and 7 after admission, on the day of maximum opioid consumption, and on the day of maximum pain intensity during admission. Average values for MDPI and MEDD were calculated between Days 2 and 7. RESULTS. When age was treated as a categoric variable (< 65 years, 65-74 years, and 75 + years), statistically significant differences in MEDD were observed for age for all estimates except those for Day 7, with older patients requiring a lower equianalgesic dose. No major differences were observed for pain intensity and for the presence of incidental or neuropathic pain across the different age groups, In the multivariate analysis, the reduction in MEDD ranged between 27-71 mg when patients age greater than or equal to 75 years were compared with younger adults. A MEDD increase that ranged between 82-137 mg was associated with the presence of neuropathic pain. CONCLUSIONS. The current study suggests that elderly cancer patients may experience a similar level of pain intensity but require a lower amount of opioid analgesia than younger adults. However, because elderly patients are more likely to be affected by the acute and chronic toxicities of opioids, opioids should be initially administered at a lower dose and titrated cautiously in these patients. (C) 1998 American Cancer Society.
引用
收藏
页码:1244 / 1250
页数:7
相关论文
共 50 条
  • [21] Meaningful cut-off pain intensity for breakthrough pain changes in advanced cancer patients
    Mercadante, Sebastiano
    Adile, Claudio
    Torta, Riccardo
    Varetto, Antonella
    Fulfaro, Fabio
    Giarratano, Antonino
    Casuccio, Alessandra
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (01) : 93 - 97
  • [22] Strong opioid and cancer pain: Galenics and dose conversion
    Beziaud, Nicolas
    Pellat, Jean-Michel
    Villard, Marie-Laure
    Liatard, Karine
    Laval, Guillemette
    MEDECINE PALLIATIVE, 2009, 8 (01): : 27 - 34
  • [23] Analysis of dose intensity in elderly patients with advanced cancer:: A single center experience
    Luciani, A.
    Marussi, D.
    Fumagalli, L.
    Tartaro, T.
    Oldani, S.
    Caldiera, S.
    Zonato, S.
    Ferrari, D.
    Codeca, C.
    Foa, P.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 60 : S32 - S32
  • [24] Effect of gene variants on opioid dose, pain and adverse effect outcomes in advanced cancer: an explorative study
    Wong, Aaron K.
    Klepstad, Pal
    Somogyi, Andrew A.
    Vogrin, Sara
    Le, Brian
    Philip, Jennifer
    Rubio, Justin P.
    PHARMACOGENOMICS, 2023, 24 (18) : 901 - 913
  • [25] Opioid Needs of Patients with Advanced Cancer and the Morphine Dose-Limiting Law in Egypt
    Alsirafy, Samy A.
    El-Mesidi, Salah M.
    El-Sherief, Wesam A.
    Galal, Khaled M.
    Abou-Elela, Enas N.
    Aklan, Nahla A.
    JOURNAL OF PALLIATIVE MEDICINE, 2011, 14 (01) : 51 - 54
  • [26] Opioid-induced or pain relief-reduced symptoms in advanced cancer patients?
    Mercadante, S
    Villari, P
    Ferrera, P
    Casuccio, A
    EUROPEAN JOURNAL OF PAIN, 2006, 10 (02) : 153 - 159
  • [27] Treatment Intensity, not Age, Affects Survival Time of Patients with Advanced Pancreatic Cancer
    Kunkel, Jonas
    Bohle, Wolfram
    Henseling, Silja
    Zoller, Wolfram G.
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2021, 30 (03) : 380 - 387
  • [28] CANCER PAIN SELF-MANAGEMENT IN THE CONTEXT OF A NATIONAL OPIOID EPIDEMIC: EXPERIENCES OF PATIENTS WITH ADVANCED CANCER
    Azizoddin, Desiree R.
    Knoerl, Rober
    Adam, Rosalind
    Kessler, Daniela
    Enzinger, Andrea C.
    Tulsky, James A.
    ANNALS OF BEHAVIORAL MEDICINE, 2021, 55 : S90 - S90
  • [29] Factors influencing constipation in advanced cancer patients: a prospective study of opioid dose, dantron dose and physical functioning
    Bennett, M
    Cresswell, H
    PALLIATIVE MEDICINE, 2003, 17 (05) : 418 - 422
  • [30] THE IMPORTANCE OF DOSE INTENSITY IN CHEMOTHERAPY OF ADVANCED TESTICULAR CANCER
    MIYANAGA, N
    AKAZA, H
    HATTORI, K
    TAKESHIMA, H
    KOISO, K
    UROLOGIA INTERNATIONALIS, 1995, 54 (04) : 220 - 225